Pharmacokinetics of Lopinavir in HIV Type-1-Infected Children Taking the New Tablet Formulation Once Daily

Autor: David M. Burger, Linda C. van der Knaap, Manon J. van der Lee, Gertjan J. Driessen, Gwenda Verweel, Nico G. Hartwig, Petronette van Jaarsveld, Michiel van der Flier

Publikováno v: Antiviral Therapy. 13:1087-1090

BackgroundRecently, a new tablet formulation of the widely used HIV protease inhibitor lopinavir/ritonavir was licensed. Here, we present a pilot study of the pharmaco-kinetics of the new adult tablet formulation taken once daily in children.MethodsL

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f912279736a6e5f6f52fdf40690cd1a
https://doi.org/10.1177/135965350801300819

Initiating Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Children in Europe and the United States

Autor: Ronald de Groot, Annemarie M. C. van Rossum, Gwenda Verweel, Octavio Ramilo, Jesús Saavedra-Lozano

Publikováno v: Pediatric Infectious Disease Journal. 25:987-994

Several guidelines are available to guide the initiation of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV)-infected children. The recommendations in these guidelines show significant variability. Because there is n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af2407fffc2729b720bd9eda666eb141
https://doi.org/10.1097/01.inf.0000242670.11693.56

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children

Autor: Tim Niehues, David M. Burger, Pieter L. A. Fraaij, Gwenda Verweel, Nico G. Hartwig, Ronald de Groot, Alina S. Bergshoeff, Jennifer Ndagijimana

Publikováno v: JAIDS : Journal of Acquired Immune Deficiency Syndromes, 39, 1, pp. 63-8
JAIDS : Journal of Acquired Immune Deficiency Syndromes, 39, 63-8
Jaids. Journal of Acquired Immune Deficiency Syndromes, 39(1), 63-68. Lippincott Williams & Wilkins

Contains fulltext : 48066.pdf (Publisher’s version ) (Closed access) BACKGROUND: Nucleoside reverse transcriptase inhibitor-sparing regimens have not yet been systematically evaluated in children. The nonnucleoside reverse transcriptase inhibitors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4f046f6579ed4f27ab798dd076f51e2
https://doi.org/10.1097/01.qai.0000155203.89350.85

Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily

Autor: Michiel, van der Flier, Gwenda, Verweel, Linda C, van der Knaap, Petronette, van Jaarsveld, Gert-Jan, Driessen, Manon, van der Lee, Nico G, Hartwig, David M, Burger

Publikováno v: Antiviral therapy. 13(8)

Recently, a new tablet formulation of the widely used HIV protease inhibitor lopinavir/ritonavir was licensed. Here, we present a pilot study of the pharmacokinetics of the new adult tablet formulation taken once daily in children.Lopinavir pharmacok

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5261f5fc7300e4d65aefd55fd0faa86f
https://pubmed.ncbi.nlm.nih.gov/19195335

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below

Autor: Ronald de Groot, Nico G. Hartwig, Gwenda Verweel, Adilia Warris, David M. Burger, Alina S. Bergshoeff, Nancy L. Sheehan, Linda C Van Der Knaap, Gertjan J. Driessen

Publikováno v: Antiviral Therapy, 12, 4, pp. 453-8
Antiviral Therapy, 12, 453-8
Antiviral Therapy, 12(4), 453-458. International Medical Press Ltd

BackgroundLopinavir/ritonavir (LPV/r) has been licensed for the treatment of HIV-infected children >6 months in the US and >2 years in the EU. Limited LPV paediatric pharmacokinetic data are available. We studied LPV pharmacokinetics to determine whe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97e71a89ea29cf6dcb0b31180300c42
https://hdl.handle.net/2066/52704